Abstract:It is now little disputed that most if not all cancer cells express antigens that can be recognized by specific CD8(+) T lymphocytes. However, a central question in the field of anti-tumor immunity is why such antigen-expressing tumors are not spontaneously eliminated by the immune system. While in some cases, this lack of rejection may be due to immunologic ignorance, induction of anti-tumor T-cell responses in many patients has been detected in the peripheral blood, either spontaneously or in response to vaccination, without accompanying tumor rejection. These observations argue for the importance of barriers downstream from initial T-cell priming that need to be addressed to translate immune responses into clinical tumor regression. Recent data suggest that the proper trafficking of effector T cells into the tumor microenvironment may not always occur. T cells that do effectively home to tumor metastases are often found to be dysfunctional, pointing toward immunosuppressive mechanisms in the tumor microenvironment. T-cell anergy due to insufficient B7 costimulation, extrinsic suppression by regulatory cell populations, inhibition by ligands such as programmed death ligand-1, metabolic dysregulation by enzymes such as indoleamine-2,3-dioxygenase, and the action of soluble inhibitory factors such as transforming growth factor-beta have all been clearly implicated in generating this suppressive microenvironment. Identification of these downstream processes points to new therapeutic targets that should be manipulated to facilitate the effector phase of anti-tumor immune responses in concert with vaccination or T-cell adoptive transfer.

T cell dysfunction in cancer immunity and immunotherapy

Cancer Immunotherapies Targeting Tumor-Associated Regulatory T Cells

T Cell Dysfunction and Exhaustion in Cancer

T cell dysfunction and therapeutic intervention in cancer

T-cell exhaustion and stemness in antitumor immunity: Characteristics, mechanisms, and implications

Dysfunction of dendritic cells in tumor microenvironment and immunotherapy

Disturbance of Differentiation and Maturation of Dendritic Cells and Tumor Escape

CD8+ T cell differentiation and dysfunction in cancer

Reversing T-cell Dysfunction and Exhaustion in Cancer

T Cell Anergy, Exhaustion, Senescence, and Stemness in the Tumor Microenvironment

Impaired function of dendritic cells within the tumor microenvironment

T cell exhaustion in human cancers

The Interplay between T Cells and Cancer: The Basis of Immunotherapy

New opportunities to overcome T cell dysfunction: the role of transcription factors and how to target them

NK Cell Dysfunction and Checkpoint Immunotherapy

Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy

CD8+ T cell states in human cancer: insights from single-cell analysis

CD8+ T cell exhaustion and its regulatory mechanisms in the tumor microenvironment: key to the success of immunotherapy

Immune resistance orchestrated by the tumor microenvironment

Dendritic cells dysfunction in tumor-draining lymph nodes

Novel Tumor Immunotherapy: Targeting Dysfunctional Antigen Presenting Cells.